At a Glance
- Company: Eli Lilly; Centessa Pharmaceuticals (NASDAQ: CNTA)
- Location: Indianapolis (Lilly); London/US (Centessa)
- Deal value: $6.3 billion upfront plus potential milestones
- Focus area: ORX750 orexin-2 receptor agonist for narcolepsy and sleep disorders
- Next steps: Complete acquisition; advance ORX750 toward regulatory filing
What happened?
Eli Lilly has agreed to acquire Centessa Pharmaceuticals for $6.3 billion upfront in its latest neuroscience push, gaining the rights to ORX750, Centessa’s lead orexin-2 receptor agonist candidate. The deal marks Lilly’s most significant CNS transaction in recent years, deepening its commitment to sleep and neuroscience alongside its blockbuster metabolic portfolio.
Why does it matter?
The orexin receptor agonist space is rapidly emerging as one of the most commercially promising areas in sleep medicine, following the clinical validation of Takeda’s Wakix and the entry of Jazz Pharmaceuticals’ Lumryz. ORX750 is designed to directly restore orexin signalling lost in narcolepsy type 1, offering a potential disease-aligned mechanism superior to existing stimulants and sodium oxybate therapies. Analysts have projected the narcolepsy market could exceed $5 billion by 2030, making Centessa a highly attractive asset at this stage of development.
Who’s behind it?
Centessa was built as a portfolio biotech model, aggregating programmes across multiple subsidiaries before narrowing its focus to ORX750 as its lead asset in narcolepsy and idiopathic hypersomnia. Lilly has been selectively building a neuroscience pipeline following earlier investments in Alzheimer’s disease via donanemab and its broader CNS ambitions, making a late-stage sleep disorder asset a natural strategic fit.
How was it achieved?
ORX750 demonstrated strong clinical activity in Phase 2 trials, showing meaningful improvements in sleep latency and excessive daytime sleepiness in narcolepsy patients with a favourable tolerability profile. The programme had secured FDA Breakthrough Therapy Designation, de-risking the regulatory path and supporting the premium valuation Lilly is prepared to pay ahead of a planned Phase 3 programme or potential NDA filing.
What’s next?
Following deal close, Lilly will assume full development and commercial responsibility for ORX750, with a focus on completing pivotal trials or regulatory submissions in narcolepsy type 1 and type 2. The company is expected to explore label expansion into idiopathic hypersomnia and other sleep-wake disorders, leveraging its commercial infrastructure to compete in a market where Takeda and Jazz currently hold dominant positions.